clinical trial · NCT06697301
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Advanced MelanomaEIK1001Pembrolizumab (KEYTRUDA® )
brief summary
The study is for patients with advanced melanoma who are eligible for standard therapy with Pembrolizumab.
started
May 22, 2025
primary completion
Dec 1, 2035
completion
Dec 1, 2040
last updated
Nov 12, 2025
detailed description
This is a Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Participants with Advanced Melanoma. The study includes dose optimization and expansion parts.
official title
A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Participants With Advanced Melanoma (TeLuRide-006)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol